Vertex enters into agreement to acquire alpine immune sciences

Boston & seattle--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and alpine immune sciences, inc. (nasdaq: alpn), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which vertex will acquire alpine for $65 per share or approximately $4.9 billion in cash. the transaction was unanimously approved by both the vertex and alpine boards of direct.
VRTX Ratings Summary
VRTX Quant Ranking